NCT00000654View on ClinicalTrials.gov

The Tolerance of HIV-Infected Patients With Herpes Group Virus Infections to Oral Doses of FIAU

PHASE2CompletedINTERVENTIONAL

Enrollment

78

Participants

Timeline

Start Date

Not specified

Study Completion Date

February 28, 1993

Conditions

Herpes SimplexHIV InfectionsHepatitis B

Interventions

DRUG

Fialuridine

Trial Locations (4)

20892

Natl Institute of Health, Bethesda

35294

Univ of Alabama at Birmingham, Birmingham

98122

Univ of Washington / Madison Clinic, Seattle

921036325

Univ of California / San Diego Treatment Ctr, San Diego

Sponsors

Collaborators (1)

Oclassen Pharmaceuticals

All Listed Sponsors

collaborator

Oclassen Pharmaceuticals

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH